The DOI matches its Crossref record.
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Open accessAbstract
The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Food and Drug Administration (CFDA) as a treatment for relapsed or refractory peripheral T cell lymphoma (PTCL). This study sought to further evaluate the real-world utilization of chidamide in 383 relapsed or refractory PTCL patients from April 2015 to February 2016 in mainland China. For patients receiving chidamide monotherapy (n = 256), the overall response rate (ORR) and disease control rate (DCR) were 39.06 and 64.45%, respectively. The ORR and DCR were 51.18 and 74.02%, respectively, for patients receiving chidamide combined with chemotherapy (n = 127). For patients receiving chidamide monotherapy and chidamide combined with chemotherapy, the median progression-free survival (PFS) was 129 (95% CI 82 to 194) days for the monotherapy group and 152 (95% CI 93 to 201) days for the combined therapy group (P = 0.3266). Most adverse events (AEs) were of grade 1 to 2. AEs of grade 3 or higher that occurred in ≥5% of patients receiving chidamide monotherapy included thrombocytopenia (10.2%) and neutropenia (6.2%). For patients receiving chidamide combined with chemotherapy, grade 3 to 4 AEs that occurred in ≥5% of patients included thrombocytopenia (18.1%), neutropenia (12.6%), anemia (7.1%), and fatigue (5.5%). This large real-world study demonstrates that chidamide has a favorable efficacy and an acceptable safety profile for refractory and relapsed PTCL patients. Chidamide combined with chemotherapy may be a new treatment choice for refractory and relapsed PTCL patients but requires further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Histone deacetylase 6 in cancer
Li, T., Zhang, C., Hassan, S., Liu, X., Song, F., Chen, K., Zhang, W., & Yang, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0654-9 · Cited by 326
Self-citationLysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease
Li, P., Ge, J., & Li, H. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0235-9 · Cited by 269
Liu, R., Wu, J., Guo, H., Yao, W., Li, S., Lu, Y., Jia, Y., Liang, X., Tang, J., & Zhang, H. (2023) · MedComm · doi:10.1002/mco2.292 · Cited by 264
Self-citationHistone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112171 · Cited by 121
Metadata
- Authors
- Shi, Y., Jia, B., Xu, W., Li, W., Liu, T., Liu, P., Zhao, W., Zhang, H., Sun, X., Yang, H., Zhang, X., Jin, J., Jin, Z., Li, Z., Qiu, L., Dong, M., Huang, X., Luo, Y., Wang, X., Wang, X., Wu, J., Xu, J., Yi, P., Zhou, J., He, H., Liu, L., Shen, J., Tang, X., Wang, J., Yang, J., Zeng, Q., Zhang, Z., Cai, Z., Chen, X., Ding, K., Hou, M., Huang, H., Li, X., Liang, R., Liu, Q., Song, Y., Su, H., Gao, Y., Liu, L., Luo, J., Su, L., Sun, Z., Tan, H., Wang, H., Wang, J., Wang, S., Zhang, H., Zhang, X., Zhou, D., Bai, O., Wu, G., Zhang, L., & Zhang, Y.
- Venue
- Journal of Hematology & Oncology
- Published
- 2017-03-15
- Volume
- 10
- Issue
- 1
- Pages
- 69-69
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W2601168549
- Cited by
- 246
- References
- 0
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. https://app.cochat.ai/papers/10.1186/s13045-017-0439-6
- The paper
- Shi, Y., Jia, B., Xu, W., Li, W., Liu, T., Liu, P., Zhao, W., Zhang, H., Sun, X., Yang, H., Zhang, X., Jin, J., Jin, Z., Li, Z., Qiu, L., Dong, M., Huang, X., Luo, Y., Wang, X., . . . Zhang, Y. (2017). Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-017-0439-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.